DOT1 Antibody

What is DOT1L and why is it important in epigenetic research?

DOT1L is the mammalian homologue of the yeast Dot1 protein and the Drosophila Grappa protein. Unlike most histone lysine methyltransferases, DOT1L does not contain a SET domain but instead shares structural similarity with arginine methyltransferases while specifically catalyzing lysine methylation . DOT1L is the sole enzyme responsible for mono-, di-, and trimethylation of lysine 79 on histone H3 (H3K79), making it a critical epigenetic regulator. Its importance stems from its roles in transcriptional regulation, cell cycle progression, DNA damage response, and development . DOT1L has been implicated in leukemogenesis through interactions with MLL fusion proteins, making it both a significant research target and potential therapeutic target .

Which region of DOT1L should I target with an antibody for optimal detection?

The choice of target region depends on your specific experimental goals. For general detection, antibodies targeting the C-terminal region of human DOT1L have been validated for Western blotting applications . For studies involving protein interactions or functional domains, consider antibodies targeting specific amino acid sequences such as AA 3-108, AA 331-484, or AA 1390-1420 (C-Term) . When studying conserved functions across species, target regions with high sequence homology between your species of interest. Always verify that your chosen antibody has been validated in your application of interest (Western blot, IHC, etc.) and confirm that the epitope is not masked by protein interactions or post-translational modifications in your experimental context.

How do I optimize sample preparation for DOT1L detection in Western blotting?

For optimal DOT1L detection in Western blotting, proper sample preparation is crucial. Begin by extracting nuclear proteins since DOT1L is primarily located in the nucleus. Use a lysis buffer containing protease inhibitors to prevent degradation of target proteins. Since DOT1L is a large protein (~165 kDa), use a lower percentage (6-8%) SDS-PAGE gel for better resolution of high molecular weight proteins. For transfer, consider using a wet transfer system with extended transfer time or reduced voltage to ensure complete transfer of large proteins. Prior to immunoblotting, check transfer efficiency using Ponceau S staining. When probing with anti-DOT1L antibody, optimize primary antibody concentration (typically 1:500 to 1:2000 dilution) and extend incubation time to overnight at 4°C for improved signal-to-noise ratio . Include appropriate controls, such as DOT1L knockout or knockdown samples, to confirm antibody specificity.

What controls should I include when using DOT1L antibodies?

Including appropriate controls is essential for validating DOT1L antibody specificity. Primary controls should include a positive control (cell line or tissue with known DOT1L expression), negative control (DOT1L knockout or knockdown samples), and technical controls (omitting primary antibody). For functional studies, include controls with DOT1L inhibitors like Pinometostat (EPZ-5676) at 10 µM concentration, which allows comparison between DOT1L activity and inhibition . When studying H3K79 methylation, include histone extraction controls and H3 total protein controls to normalize methylation levels. For immunoprecipitation experiments, include IgG isotype controls matching your DOT1L antibody host species. In genetic studies, compare wild-type samples with Dot1L-KO samples, as demonstrated in studies of B-cell differentiation where Dot1L-KO B cells showed distinct phenotypic differences .

How can I distinguish between different methylation states of H3K79 when using DOT1L antibodies?

Distinguishing between the mono-, di-, and trimethylation states of H3K79 requires the use of modification-specific antibodies rather than DOT1L antibodies themselves. DOT1L antibodies detect the enzyme responsible for these modifications but cannot directly distinguish between methylation states. To accurately profile H3K79 methylation states, employ specifically validated antibodies against H3K79me1, H3K79me2, and H3K79me3. When analyzing methylation state changes in response to DOT1L inhibition or manipulation, use quantitative immunoblotting with these modification-specific antibodies normalized to total H3 levels. For precise quantification, consider techniques like mass spectrometry to determine the relative abundance of each methylation state. ChIP-seq using methylation state-specific antibodies can map genome-wide distribution of different H3K79 methylation states and correlate them with transcriptional activity. When interpreting results, remember that DOT1L processively catalyzes all three methylation states, and the balance between them may have distinct biological implications in different cellular contexts .

What are the considerations for using DOT1L antibodies in ChIP experiments?

Chromatin immunoprecipitation (ChIP) with DOT1L antibodies presents several technical challenges. First, select an antibody validated specifically for ChIP applications, as not all DOT1L antibodies work efficiently for chromatin immunoprecipitation. Optimize crosslinking conditions, as DOT1L interacts with nucleosomes rather than directly binding DNA. Standard formaldehyde crosslinking (1% for 10 minutes) may be sufficient, but dual crosslinking with disuccinimidyl glutarate (DSG) followed by formaldehyde can improve results for protein-protein interactions. Sonication conditions must be carefully optimized to generate 200-500 bp fragments without destroying epitopes. For DOT1L ChIP-seq, use appropriate controls including input chromatin, IgG control, and ideally a DOT1L-depleted control. Consider the relationship between DOT1L and H2B ubiquitination, as research has shown that Dot1 promotes H2B ubiquitination through a methyltransferase-independent mechanism . This relationship may affect interpretation of your results. Finally, when analyzing ChIP-seq data, correlate DOT1L binding with H3K79 methylation patterns and gene expression data for comprehensive understanding of DOT1L function in your experimental system.

How can I effectively study DOT1L interactions with other proteins using co-immunoprecipitation?

To effectively study DOT1L interactions with other proteins, optimize your co-immunoprecipitation (co-IP) protocol for this large nuclear protein. Begin with gentle cell lysis using a buffer containing 150-300 mM NaCl, 0.5% NP-40 or 1% Triton X-100, and protease inhibitors to preserve protein complexes. Pre-clear lysates with protein A/G beads to reduce non-specific binding. For the co-IP, use 2-5 μg of DOT1L antibody per 500 μg-1 mg of protein lysate, incubating overnight at 4°C with gentle rotation. When studying MLL fusion interactions with DOT1L, which are implicated in leukemogenesis, consider crosslinking approaches to stabilize transient interactions . For B-cell specific studies, investigate interactions with transcriptional regulators like BACH2 and MYC, as well as epigenetic modifiers like EZH2 (a PRC2 component), which have been identified as functionally relevant in DOT1L-mediated B-cell differentiation . Validate interactions using reciprocal co-IPs and consider proximity ligation assays (PLA) as an alternative approach to visualize protein interactions in situ. Always include appropriate controls: IgG isotype control, input sample (5-10% of starting material), and when possible, samples from DOT1L knockout or knockdown systems.

What are the technical considerations when comparing DOT1L function across different species models?

When comparing DOT1L function across species, several technical considerations must be addressed. First, verify antibody cross-reactivity, as not all DOT1L antibodies recognize orthologs across species. The conserved methyltransferase domain (containing motifs I, post I, II, and III found in SAM methyltransferases) shows higher sequence conservation than N-terminal regions, making it a better target for cross-species comparisons . Be aware of structural and functional differences - while yeast Dot1 and human DOT1L share core enzymatic functions, their regulatory mechanisms and protein interactions may differ significantly. For example, in yeast, Dot1 was identified in genetic screens for telomeric silencing disruption, while mammalian DOT1L has broader roles in development and hematopoiesis . When designing experiments, consider species-specific contexts: H3K79 methylation by Dot1 affects telomeric silencing in yeast through interactions with Sir proteins, while in mammals, DOT1L regulates developmental processes and hematopoiesis . Optimize experimental conditions for each species model, including extraction methods, antibody concentrations, and incubation times. Finally, interpret results in the context of species-specific biology - DOT1L knockout is lethal in mice, highlighting its essential developmental roles in mammals, whereas yeast can tolerate Dot1 deletion with specific phenotypic consequences .

How does inhibition of DOT1L enzymatic activity affect various cellular processes, and how can I measure these effects?

Inhibition of DOT1L enzymatic activity has profound effects on multiple cellular processes that can be measured using various methodological approaches. For transcriptional analysis, perform RNA-seq before and after DOT1L inhibition with compounds like Pinometostat (EPZ-5676) at 10 μM to identify DOT1L-dependent gene expression programs . When studying hematopoietic cells, assess differentiation markers by flow cytometry, as DOT1L inhibition in B cells leads to aberrant differentiation and premature acquisition of plasma cell characteristics . For epigenomic analysis, combine ChIP-seq for H3K79me1/2/3 with ATAC-seq to correlate changes in chromatin accessibility with loss of H3K79 methylation. To study cell cycle effects, perform BrdU incorporation assays and cell cycle analysis by flow cytometry, as DOT1L regulates cell cycle progression. In leukemia models, particularly those driven by MLL fusion proteins, assess cell proliferation, colony formation, and apoptosis following DOT1L inhibition . For B cell-specific studies, measure class-switch recombination frequency and plasma cell formation after DOT1L inhibition, using CTV dilution to track cell division simultaneously . Finally, for in vivo studies of immune responses, assess germinal center formation, antibody titers, and plasma cell generation following immunization of DOT1L-deficient models, as DOT1L is essential for establishing normal humoral immune responses .

What are common causes of non-specific binding with DOT1L antibodies and how can they be mitigated?

Non-specific binding with DOT1L antibodies can arise from several sources. First, inadequate blocking may allow primary or secondary antibodies to bind non-specifically to the membrane or tissue. Optimize blocking by testing different blocking agents (5% BSA, 5% non-fat dry milk, or commercial blocking buffers) and extending blocking time to 1-2 hours at room temperature. Second, excessively high antibody concentrations can increase background signal - titrate antibody concentrations to find the optimal signal-to-noise ratio, typically starting with manufacturer recommendations and adjusting as needed. Third, cross-reactivity with related proteins may occur, particularly with polyclonal antibodies. To address this, use highly purified, affinity-purified antibodies like those derived from the C-terminal region of human DOT1L . Fourth, inadequate washing can leave residual unbound antibodies - implement more stringent washing steps (4-5 washes of 5-10 minutes each) with TBST or PBST containing 0.1-0.3% Tween-20. For applications requiring higher specificity, consider using monoclonal antibodies that recognize a single epitope. Finally, validate observed signals using DOT1L-depleted samples as negative controls, as demonstrated in studies that used DOT1L knockout models to confirm antibody specificity .

How can I optimize detection of DOT1L in different cellular compartments?

Optimizing detection of DOT1L in different cellular compartments requires specific approaches for subcellular fractionation and immunostaining. For biochemical fractionation, use a stepwise protocol that sequentially extracts cytoplasmic, nuclear soluble, and chromatin-bound proteins. Verify fractionation quality using compartment-specific markers (GAPDH for cytoplasm, Lamin B1 for nuclear membrane, Histone H3 for chromatin). Since DOT1L is primarily nuclear and associated with chromatin, optimize extraction conditions with appropriate salt concentrations (typically 300-450 mM NaCl) to release chromatin-bound DOT1L. For immunofluorescence detection, fixation method is critical - compare paraformaldehyde (4%, 10-15 minutes) with methanol fixation to determine which best preserves DOT1L epitopes while maintaining cellular architecture. Permeabilization conditions affect antibody accessibility to nuclear antigens - test Triton X-100 (0.1-0.5%) or saponin (0.1-0.3%) at various concentrations and durations. For co-localization studies, combine DOT1L immunostaining with markers of specific nuclear domains (SC35 for splicing speckles, nucleolin for nucleoli) or histone modifications (H3K79me2) to reveal functional relationships. When interpreting results, remember that DOT1L distribution may change during cell cycle progression or in response to DNA damage, necessitating cell synchronization or specific treatment conditions for consistent results .

What strategies can address poor signal-to-noise ratio in Western blots using DOT1L antibodies?

Poor signal-to-noise ratio in Western blots with DOT1L antibodies can be addressed through a systematic optimization approach. Begin by improving transfer efficiency of high molecular weight proteins by using wet transfer systems, reducing methanol concentration in transfer buffer to 10%, and adding 0.1% SDS to enhance transfer of large proteins like DOT1L (~165 kDa). Increase signal strength by extending primary antibody incubation to overnight at 4°C with gentle agitation and optimizing antibody concentration through titration experiments. Reduce background by implementing more stringent washing steps - 5-6 washes of 5-10 minutes each with TBST containing 0.1-0.3% Tween-20, and consider adding 150-500 mM NaCl to washing buffer to reduce non-specific ionic interactions. For particularly challenging detections, try signal amplification systems like biotin-streptavidin or tyramide signal amplification. If membrane autofluorescence is an issue when using fluorescent secondary antibodies, consider switching to chemiluminescent detection with film or digital imaging. For samples with low DOT1L expression, increase loading amount (up to 50-100 μg total protein) or enrich nuclear proteins through fractionation before Western blotting. Finally, consider alternative blocking agents - while 5% non-fat dry milk is standard, 5% BSA or commercial blockers may yield better results for certain antibodies .

How should results be interpreted when DOT1L antibody data conflicts with functional assays or genetic models?

When facing discrepancies between DOT1L antibody data and functional assays or genetic models, a systematic troubleshooting approach is necessary. First, critically evaluate antibody specificity through knockout/knockdown validation, as not all commercial antibodies are adequately validated. Different antibody clones targeting different DOT1L epitopes may yield conflicting results due to epitope masking by protein interactions, post-translational modifications, or conformational changes. Second, consider the possibility of compensatory mechanisms in genetic models - acute inhibition versus genetic deletion may produce different phenotypes due to adaptation in long-term DOT1L-deficient systems . Third, examine the readouts being compared - direct detection of DOT1L protein versus measurement of H3K79 methylation or downstream gene expression may not always correlate linearly. Fourth, assess technical variables such as cell type-specific effects, as DOT1L function varies between tissues (e.g., its critical role in B-cell differentiation) . Finally, consider the possibility that DOT1L may have methyltransferase-independent functions, as demonstrated by its role in promoting H2B ubiquitination through a mechanism separate from its enzymatic activity . When reporting conflicting results, document all experimental conditions thoroughly, present both sets of data transparently, and discuss potential biological explanations for the observed discrepancies.

What is the optimal protocol for detecting changes in H3K79 methylation as a readout of DOT1L activity?

Detecting changes in H3K79 methylation requires a carefully optimized protocol that begins with proper histone extraction. Use a specialized histone extraction method involving acid extraction (0.2N HCl or 0.4N H2SO4) followed by TCA precipitation to isolate histones with preserved post-translational modifications. For Western blot analysis, separate histones on 15-18% SDS-PAGE gels or specialized Triton-Acid-Urea (TAU) gels that can resolve differently modified histone species. When probing for H3K79 methylation states, use highly specific antibodies against H3K79me1, H3K79me2, or H3K79me3, and always normalize to total H3 levels loaded in the same samples. For comparative studies of DOT1L activity, treat cells with the specific DOT1L inhibitor Pinometostat (EPZ-5676) at 10 μM as a control for loss of methyltransferase activity . For genome-wide analysis, perform ChIP-seq with anti-H3K79me2 antibodies to map methylation distribution before and after experimental manipulation of DOT1L. When quantifying changes, implement quantitative immunoblotting with fluorescent secondary antibodies and appropriate standards, or consider mass spectrometry-based approaches for absolute quantification of different methylation states. Finally, correlate H3K79 methylation changes with transcriptional outcomes using RNA-seq to establish functional consequences of altered DOT1L activity .

How can DOT1L antibodies be used effectively in flow cytometry for studying cellular differentiation?

While DOT1L is primarily a nuclear protein and traditional flow cytometry for intracellular proteins can be challenging, a carefully optimized protocol can yield valuable data, particularly in differentiation studies. Begin with effective fixation and permeabilization - use 4% paraformaldehyde fixation (10 minutes) followed by permeabilization with 0.1% Triton X-100 or commercial nuclear permeabilization buffers designed to access nuclear antigens. For B cell differentiation studies, combine DOT1L staining with surface markers (B220, CD19) and differentiation markers (CD138 for plasma cells) as described in studies of DOT1L-deficient B cells . To track proliferation simultaneously, label cells with cell trace dyes before stimulation and culture. When analyzing results, create appropriate gating strategies that account for cell cycle phases, as DOT1L levels and activity may vary throughout the cell cycle. For studying DOT1L inhibition effects, include positive controls treated with LPS or anti-CD40+IL-4 and negative controls treated with DOT1L inhibitor Pinometostat at 10 μM . For quantitative analysis, use median fluorescence intensity rather than percent positive cells, as DOT1L expression changes may be gradual rather than binary. Finally, validate flow cytometry results with complementary techniques such as immunofluorescence microscopy or Western blotting to confirm specificity of the observed patterns.

What approaches can be used to study the relationship between DOT1L and histone H2B ubiquitination?

Studying the relationship between DOT1L and histone H2B ubiquitination requires integrated approaches that can detect both modifications and their functional interplay. Begin with sequential chromatin immunoprecipitation (Re-ChIP), first pulling down with anti-DOT1L antibodies followed by anti-H2Bub1 antibodies (or vice versa) to identify genomic regions where both modifications co-occur. For biochemical analysis, perform co-immunoprecipitation experiments to test if DOT1L physically interacts with the H2B ubiquitination machinery. Implement genetic approaches by comparing H2Bub1 levels in wild-type versus DOT1L-overexpressing or DOT1L-knockout cells, using quantitative immunoblotting with H2Bub1-specific antibodies normalized to total H2B levels, as demonstrated in studies showing that Dot1 promotes H2B ubiquitination . For functional studies, combine DOT1L inhibition with manipulation of H2B ubiquitination (by targeting RNF20/40 or USP22) and assess downstream effects on transcription and chromatin structure. When quantifying H2Bub1 levels by Western blot, use the ratio of H2Bub1/H2B relative to wild-type controls as shown in published studies . For mechanistic dissection, create DOT1L mutants lacking methyltransferase activity but retaining protein-protein interaction domains to test if DOT1L promotes H2B ubiquitination through a methyltransferase-independent mechanism, as suggested by research showing Dot1 can affect H2B ubiquitination independently of its catalytic function .

How can DOT1L antibodies be used in multiplexed imaging techniques for studying nuclear organization?

For multiplexed imaging of DOT1L in the context of nuclear organization, several advanced techniques can be employed. Begin with multicolor immunofluorescence combining DOT1L antibodies with antibodies against other nuclear factors or histone modifications (H3K79me2, H3K4me3, RNA Polymerase II) to study their spatial relationships. For higher resolution, implement super-resolution microscopy techniques such as Structured Illumination Microscopy (SIM) or Stochastic Optical Reconstruction Microscopy (STORM), which can resolve structures beyond the diffraction limit and provide detailed visualization of DOT1L distribution within nuclear compartments. When working with tissue sections, consider multiplexed immunohistochemistry using tyramide signal amplification, which allows sequential detection of multiple antigens on the same slide through iterative staining, imaging, and signal removal. For correlative studies of DOT1L localization with functional outcomes, combine imaging with in situ hybridization to simultaneously detect DOT1L protein and specific mRNAs of interest. When studying dynamic processes, implement live-cell imaging using cells expressing fluorescently tagged DOT1L, complemented with fixed-cell validation using DOT1L antibodies. For quantitative spatial analysis, use computational image analysis to measure co-localization coefficients, distance relationships, or clustering patterns of DOT1L with other nuclear factors. Always include appropriate controls for antibody specificity, including DOT1L-deficient samples and secondary antibody-only controls .

How should DOT1L antibodies be used in leukemia research where DOT1L is implicated as a therapeutic target?

In leukemia research, DOT1L antibodies serve critical functions beyond basic detection. For mechanistic studies of MLL-fusion driven leukemias, use DOT1L antibodies in ChIP-seq experiments to map genomic binding sites of DOT1L in leukemic versus normal hematopoietic cells, correlating with H3K79me2 distribution and expression of leukemic driver genes . When evaluating DOT1L inhibitors such as Pinometostat (EPZ-5676), implement quantitative immunoblotting for H3K79 methylation states to confirm target engagement, using 10 μM concentration as demonstrated in B-cell studies . For patient sample analysis, optimize immunohistochemistry protocols for bone marrow biopsies, comparing DOT1L expression and H3K79 methylation patterns between different leukemia subtypes and normal controls. When studying drug resistance mechanisms, use DOT1L antibodies in co-immunoprecipitation experiments to identify altered protein interactions in resistant cells. For functional genomics screens, combine CRISPR-Cas9 targeting of DOT1L-associated factors with immunoblotting to identify synthetic lethal interactions. In xenograft models treated with DOT1L inhibitors, perform immunohistochemistry on harvested tissues to correlate DOT1L inhibition with therapeutic response. When analyzing primary patient samples, consider flow cytometry with DOT1L antibodies combined with leukemic markers to assess heterogeneity in DOT1L expression and activity across subpopulations of leukemic cells .

What considerations are important when using DOT1L antibodies to study B-cell differentiation and immune responses?

When studying B-cell differentiation and immune responses with DOT1L antibodies, several specific considerations are important. First, select antibodies validated in relevant B-cell populations, as epitope accessibility may differ between cell types. For flow cytometry applications, combine DOT1L staining with lineage markers (B220, CD19) and differentiation stage markers (IgM, IgD, CD138) to correlate DOT1L expression with B-cell developmental stages . When studying class-switch recombination, implement a protocol using LPS (5 μg/ml) or LPS+IL-4 (10 ng/ml) stimulation for IgG3 and IgG1 switching, respectively, as detailed in studies of DOT1L-deficient B cells . For in vivo immunization experiments, consider models that allow conditional deletion of DOT1L specifically in B cells, such as the Mb1-Cre system used to demonstrate DOT1L's essential role in mounting efficient antibody responses to T-cell-dependent antigens . When analyzing germinal center formation, employ immunohistochemistry with DOT1L antibodies alongside germinal center markers (BCL6, CD95) on lymphoid tissue sections. For mechanistic studies, use ChIP-seq with DOT1L antibodies to identify direct targets in B cells, focusing on genes involved in the pro-proliferative, pro-germinal center program and the relationship with Polycomb Repressor Complex 2 targets, as DOT1L has been shown to support repression of PRC2 target genes in B cells .

How can DOT1L antibodies be integrated with other molecular techniques for comprehensive epigenetic profiling?

Integrating DOT1L antibodies with complementary molecular techniques enables comprehensive epigenetic profiling that reveals broader regulatory networks. Begin with multi-omics approaches by combining ChIP-seq using DOT1L antibodies with ATAC-seq to correlate DOT1L binding with chromatin accessibility, and RNA-seq to link these patterns to transcriptional outcomes. For higher resolution chromatin interaction analysis, implement HiChIP using DOT1L antibodies to capture three-dimensional chromatin contacts associated with DOT1L-bound regions. To study the interplay between different histone modifications, perform sequential ChIP (Re-ChIP) with antibodies against DOT1L followed by antibodies against other histone modifications (H3K4me3, H3K27ac) or chromatin remodelers. For single-cell applications, adapt DOT1L ChIP protocols for low input material or implement CUT&Tag methods, which can work with significantly fewer cells than traditional ChIP. When studying the relationship between DOT1L and DNA methylation, combine DOT1L ChIP-seq with whole-genome bisulfite sequencing or reduced representation bisulfite sequencing. For functional validation of DOT1L target genes, integrate CRISPR interference or activation systems targeting DOT1L-bound regulatory elements with immunoblotting for DOT1L and H3K79 methylation. Finally, implement proteomics approaches such as DOT1L proximity labeling (BioID or APEX) followed by mass spectrometry to identify the complete interactome of DOT1L in your cellular context, providing insights into how DOT1L's functions are regulated through protein-protein interactions .